

COM-2024-043

1  
July  
2024

# PLEASE REVIEW Drug Information

PharmPix Clinical Department

## Drug Information:

Remember that medical literature is dynamic and is continuously changing as new scientific knowledge is developed. We exhort the frequent revision of treatment guidelines to assure that your recommendations are consistent with the most updated information.

It is our priority to offer high-quality services and support practices for health promotion and disease prevention. If you have any questions or wish to have more information regarding this document, you can call us directly or view PharmPix communications online.

### QUESTIONS

Call us at 787-522-5252, ext. 219.

Access our recent communications at our providers' portal:  
<https://www.pharmpix.com/providers/>.



PharmPix is committed to the health and wellness of our members.

The clinical team wants to communicate the latest up-to-date drug information requested.

## First Authorized Generic for a GLP-1 Receptor Agonist

Teva Pharmaceuticals, Inc. announced the launch of an authorized generic formulation of liraglutide (Victoza). This generic version of Victoza is the first-ever generic GLP-1 Receptor Agonist.

### What is Liraglutide?

Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus (T2DM); and to reduce the risk of major adverse cardiovascular (CV) events in adults with T2DM and established CV disease.

Victoza comes as a solution in a pre-filled, single-patient-use pen that delivers doses of 0.6 mg, 1.2 mg, or 1.8 mg. It is injected subcutaneously once-daily at any time of day, independently of meals, in the abdomen, thigh or upper arm

### New Generic Version Available

By launching an authorized generic for Victoza™ (liraglutide injection 1.8mg), patients with type 2 diabetes are being provided another option for their treatment. Having a generic option may provide patients a cost-saving alternative to treat their diabetes. Generic alternatives have the same active and inactive ingredients as the brand name drug. Additionally, with the introduction of Teva's authorized generic, it could stimulate market competition, potentially leading to further price reductions.



If you have any questions or wish to have more information regarding this document, you can call us at 787-522-5252-ext 219. Our pharmacists will help you. In addition, know that you can access our recent communications at our providers' portal: <https://www.pharmpix.com/providers/>.

PharmPix Drug Information Communication Number COM-2024-043 July 2024



REFERENCES:

1. National Institutes of Health. (n.d.). Liraglutide Injection. U.S. National Library of Medicine. <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14bf9812-14ee-46ce-93b1-686e4906cbbc>
2. Gallagher, A. (2024, June 28). Teva Launches Generic Formulation of Liraglutide in US. Pharmacy Times. <https://www.pharmacytimes.com/view/teva-launches-generic-formulation-of-liraglutide-in-us>
3. Kaylor, A. (2024, June 27). Teva launches authorized generic of Victoza in the US. Pharma News Intelligence. <https://pharmanewsintel.com/news/teva-launches-authorized-generic-of-victoza-in-the-us>

